ACU-D1 is under development for the treatment of severe acne rosacea and HPV associated vulvar and perianal lesions in people with HIV. The drug candidate is a cinnamate compound. The drug candidate ...

Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success ...

Researchers say a compound called SYM2081 inhibits inflammation-driving mast cells in mice and human skin samples paving the ...